European DPWG Guidelines Advance Pharmacogenomic Implementation Across the Continent
This paper from the Dutch Pharmacogenetics Working Group describes European efforts to translate pharmacogenomic test results into actionable clinical guidelines, addressing a key barrier to clinical uptake identified in healthcare professional surveys. The DPWG approach of gene-drug interaction tables with specific dose recommendations has been adopted in the Netherlands and influenced EU-wide practice. For laboratories, the paper provides the regulatory and clinical context for reporting PGx results according to European guideline standards.
The original study
Pharmacogenetic Information in Clinical Guidelines: The European Perspective.
- Authors
- Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al.
- Journal
- Clinical pharmacology and therapeutics
- Type
- Journal Article, Research Support, Non-U.S. Gov't, Review
- PMID
- 29460273
Original abstract
Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).1-3 In addition, patients are willing to consent to participate in PGx implementation studies.4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test.1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients.5,6.